← All trials
NCT06960928
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 18, 2025
- Primary completion
- Nov 30, 2026
- Completion date
- Nov 30, 2026
- First posted
- May 7, 2025
- Last posted
- Jul 18, 2025
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- Icahn School of Medicine at Mount SinaiSponsor investigator
- Icahn School of Medicine at Mount SinaiOfficial
- PolyBio Research FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.